Special Issues

Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 26,800 new cases of multiple myeloma were diagnosed in 2015, and 11,240 deaths were attributed to the disease.
Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 26,800 new cases of multiple myeloma were diagnosed in 2015, and 11,240 deaths were attributed to the disease.
Lung cancer is the second most common cancer in the United States. In 2015, an estimated 221,200 new cases of lung cancer were diagnosed, representing 13.3% of all new cancer cases.
Multiple myeloma is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 26,800 new cases of multiple myeloma were diagnosed in 2015, and 11,240 deaths were attributed to multiple myeloma in the same year.
A critical part of care planning for patients with cancer is the prevention and management of chemotherapy-induced nausea and vomiting (CINV), one of the most feared side effects of chemotherapy. Overall, 70% to 80% of patients with cancer experience CINV in the absence of appropriate CINV prophylaxis.
Colony-stimulating factors (CSFs) are endogenous glycoproteins that regulate the production and the functioning of infection-protective granulocytes and macrophages. Overall, 2 types of recombinant CSF drugs—granulocyte CSF (filgrastim, pegfilgrastim) and granulocyte-macrophage CSF (sargramostim)—have been prescribed for more than 20 years to stimulate neutrophils and macrophages, primarily in patients with cancer who are undergoing treatment with cytotoxic chemotherapy.
The year 2015 marked a noteworthy 12-month period for oncology drugs approved by the US Food and Drug Administration (FDA). The Center for Drug Evaluation and Research, which reviews the approval of antibodies and small molecules, approved a total of 45 new drugs in 2015; 15 of which are indicated for the treatment of cancer.
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) that has undergone a major evolution over the past decade.
Page 3 of 3
Results 21 - 28 of 28